Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Gilead Sciences Inc (GILD)

62.75   -0.26 (-0.41%) 03-03 16:46
Open: 62.7889 Pre. Close: 63.01
High: 63.32 Low: 62.18
Volume: 6,801,383 Market Cap: 78,851M
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 63.649 - 63.894 63.894 - 64.175
Low: 61.681 - 61.945 61.945 - 62.248
Close: 62.519 - 62.943 62.943 - 63.43

Technical analysis

as of: 2021-03-03 4:04:32 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 77.46     One year: 81.01
Support: Support1: 61.39    Support2: 51.08
Resistance: Resistance1: 66.32    Resistance2: 69.36
Pivot: 64.32
Moving Average: MA(5): 62.53     MA(20): 64.94
MA(100): 61.96     MA(250): 68.41
MACD: MACD(12,26): -0.50     Signal(9): -0.06
Stochastic oscillator: %K(14,3): 20.45     %D(3): 13.12
RSI: RSI(14): 43.81
52-week: High: 85.97  Low: 56.56  Change(%): -17.2
Average Vol(K): 3-Month: 893959  10-Days: 714025

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
GILD has closed above bottom band by 30.6%. Bollinger Bands are 23.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 01 Mar 2021
Gilead Sciences Inc. stock rises Monday, still underperforms market - MarketWatch

Fri, 26 Feb 2021
Gilead Sciences Inc. stock falls Friday, underperforms market - MarketWatch

Thu, 25 Feb 2021
Gilead Sciences Inc. stock falls Thursday, still outperforms market - MarketWatch

Thu, 18 Feb 2021
Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire

Tue, 16 Feb 2021
Gilead Sciences Inc. (GILD) Dips 3.12% for February 16 - Equities.com

Tue, 16 Feb 2021
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers General
Shares Out. (M) 1,250
Shares Float (M) 1,250
% Held by Insiders 0.11
% Held by Institutions 80.07
Shares Short (K) 22,370
Shares Short P. Month (K) 17,670

Stock Financials

EPS 1.010
EPS Est This Year 8.790
EPS Est Next Year 7.340
Book Value (p.s.) 13.920
Profit Margin 5.48
Operating Margin 21.36
Return on Assets (ttm) 5.2
Return on Equity (ttm) 6.5
Qtrly Rev. Growth 17.4
Gross Profit (p.s.) 14.216
Sales Per Share 18.520
EBITDA (p.s.) 5.080
Qtrly Earnings Growth
Operating Cash Flow (M) 8,830
Levered Free Cash Flow (M) 4,140

Stock Valuations

PE Ratio 62.39
PEG Ratio
Price to Book value 4.53
Price to Sales 3.40
Price to Cash Flow 8.92

Stock Dividends

Dividend 2.670
Forward Dividend 2.720
Dividend Yield 0.04
Dividend Pay Date 2020-12-29
Ex-Dividend Date 2020-12-13
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.